[{"id":"6440bd6a-571a-4ca7-8a63-d023b758b108","acronym":"","url":"https://clinicaltrials.gov/study/NCT03905148","created_at":"2023-04-15T20:09:41.975Z","updated_at":"2025-02-25T15:34:24.106Z","phase":"Phase 1","brief_title":"Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors","source_id_and_acronym":"NCT03905148","lead_sponsor":"BeiGene","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib) • lifirafenib (BGB-283)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-10-26"},{"id":"a3c389fe-f734-4f3d-9c9e-b893139232ad","acronym":"BGB-283-AU-001","url":"https://clinicaltrials.gov/study/NCT02610361","created_at":"2021-01-18T12:40:56.147Z","updated_at":"2024-07-02T16:36:47.712Z","phase":"Phase 1a/1b","brief_title":"Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors","source_id_and_acronym":"NCT02610361 - BGB-283-AU-001","lead_sponsor":"BeiGene","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lifirafenib (BGB-283)"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 11/20/2013","start_date":" 11/20/2013","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 10/01/2017","study_completion_date":" 10/01/2017","last_update_posted":"2020-03-25"},{"id":"b396d1c9-6d7b-4157-bb59-e6bb51894cfd","acronym":"BGB-283-CN-001","url":"https://clinicaltrials.gov/study/NCT03641586","created_at":"2021-01-18T17:52:37.814Z","updated_at":"2024-07-02T16:36:53.985Z","phase":"Phase 1","brief_title":"The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor","source_id_and_acronym":"NCT03641586 - BGB-283-CN-001","lead_sponsor":"BeiGene","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lifirafenib (BGB-283)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 10/12/2015","start_date":" 10/12/2015","primary_txt":" Primary completion: 12/06/2016","primary_completion_date":" 12/06/2016","study_txt":" Completion: 03/07/2019","study_completion_date":" 03/07/2019","last_update_posted":"2019-11-04"}]